Key Drivers
- Strong Liquidity
- Margin Compression
- Cash Conversion
AIAI Summary
INMD should now be viewed less as a clean growth-and-margin compounder and more as a cash-rich turnaround: the balance sheet and free cash flow limit downside, but the stock likely stays range-bound unless management proves the North America sales reset and international expansion can reverse margin compression and re-accelerate revenue.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Margin Compression
- •Cash Conversion
INMD has a very strong balance sheet, solid cash generation, and moderate valuation, but recent quarterly margins weakened sharply versus FY2025, making profitability stability the main risk.
Price Behavior
Key Price Behavior Insights:
- •Mid-$13s support
- •Resistance rejection
- •Lower highs
INMD remains modestly negative: mid-$13s support is holding, but repeated failures at $14.40–$14.65 keep the chart neutral-to-bearish until resistance is reclaimed.
Sharp drop on 2026-05-06 to the mid-$13s, then a tentative bounce back toward $14.05
Sentiment & News
Key News Insights:
- •Revenue growth
- •Investor outreach
- •CFO transition
InMode reported Q1 2026 revenue of $82 million, up 5% year over year, while continuing investor outreach through upcoming conferences led by finance executives.
The update signals steady operating performance and sustained capital-markets engagement, which may help support investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings